Get the Stockscreener App
74.86
0.21%
-0.155
After Hours:
75.17
0.315
+0.42%
Hologic Inc stock is traded at $74.86, with a volume of 2.12M.
It is down -0.21% in the last 24 hours and up +1.01% over the past month.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
See More
Previous Close:
$75.01
Open:
$75
24h Volume:
2.12M
Relative Volume:
0.68
Market Cap:
$16.69B
Revenue:
$4.04B
Net Income/Loss:
$557.10M
P/E Ratio:
31.06
EPS:
2.4102
Net Cash Flow:
$916.70M
1W Performance:
+0.07%
1M Performance:
+1.01%
6M Performance:
+19.63%
1Y Performance:
-2.62%
1-Day Range:
$74.55
$75.12
1-Week Range:
$74.55
$75.12
52-Week Range:
$51.90
$80.31
Hologic Inc Stock (HOLX) Company Profile
Name
Hologic Inc
Sector
Industry
Phone
(508) 263-2900
Address
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
74.86 | 16.72B | 4.04B | 557.10M | 916.70M | 2.4102 |
|
ISRG
Intuitive Surgical Inc
|
568.65 | 201.96B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
193.76 | 55.25B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
78.99 | 39.31B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
251.51 | 36.70B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
WST
West Pharmaceutical Services Inc
|
281.77 | 20.45B | 2.96B | 487.70M | 344.00M | 6.6758 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-25 | Downgrade | BNP Paribas Exane | Outperform → Neutral |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-18-25 | Upgrade | Argus | Hold → Buy |
| Aug-06-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-27-25 | Reiterated | Needham | Hold |
| Mar-03-25 | Downgrade | Argus | Buy → Hold |
| Feb-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-03-25 | Downgrade | Needham | Buy → Hold |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Dec-10-24 | Reiterated | Needham | Buy |
| Oct-01-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-24 | Initiated | Stephens | Overweight |
| Apr-03-24 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-23 | Upgrade | Needham | Hold → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-20-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-20-22 | Initiated | UBS | Neutral |
| Jul-18-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Oct-14-21 | Initiated | Redburn | Neutral |
| Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-20-20 | Downgrade | Needham | Buy → Hold |
| Nov-05-20 | Reiterated | Needham | Buy |
| Jun-30-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-03-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-30-20 | Reiterated | Needham | Buy |
| Apr-30-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-07-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Jan-31-19 | Reiterated | Needham | Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-09-18 | Initiated | UBS | Neutral |
| Sep-13-18 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Hologic Inc Stock (HOLX) Latest News
Can Hologic Inc. (HO1) stock expand revenue streams2025 Market Overview & Breakout Confirmation Alerts - Newser
Hologic's BCI Test Shows Growing Impact in Endocrine Therapy Decisions - The Globe and Mail
Spect Scanning Service Market to See Thriving Worldwide| - openPR.com
Why Is Hologic (HOLX) Up 1% Since Last Earnings Report? - Yahoo Finance
Private credit firms snap up $2bn in subordinated debt backing Blackstone and TPG’s Hologic buyout - Private Equity Insights
Hologic to present 11 studies on breast cancer test at SABCS - Investing.com Canada
Hologic to present 11 studies on breast cancer test at SABCS By Investing.com - Investing.com South Africa
PSP, Oaktree among direct lenders buying $2 billion Hologic debtBloomberg News - TradingView
PSP, Oaktree Among Direct Lenders Buying $2 Billion Hologic Debt - Bloomberg.com
Hologic (Nasdaq: HOLX) to present SABCS data on expanded Breast Cancer Index utility - Stock Titan
Is Hologic Inc. (HO1) stock in buy zone after pullbackEarnings Summary Report & Long-Term Growth Plans - Newser
Will Hologic Inc. (HO1) stock beat Nasdaq index returnsPortfolio Return Report & Fast Momentum Stock Entry Tips - Newser
Does Hologic Inc. (HO1) stock trade below intrinsic valueTake Profit & Daily Growth Stock Investment Tips - Newser
How Hologic Inc. (HO1) stock compares with market leadersJuly 2025 EndofMonth & Low Risk Entry Point Tips - Newser
What is the fair value of Hologic Inc. stock nowTrade Volume Report & Capital Protection Trade Alerts - Newser
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
New research highlights Hologic’s AI tools for mammography - DOTmed
RSNA 2025: Hologic Shares New Evidence on AI-Powered Mammography Solutions - Medical Product Outsourcing
Is Hologic Inc. stock affected by interest rate hikesQuarterly Investment Review & Low Risk Growth Stock Ideas - BỘ NỘI VỤ
Breast Health Performance Likely to Aid Hologic's Q1 Earnings - MSN
M'luru: A J Hospital & Research Centre installs advanced Hologic imaging systems for women’s health - Daijiworld
HOLX vs. DGX: Which Healthcare Diagnostics Stock Is the Better Bet? - Finviz
Why retail investors favor Hologic Inc. stockBuy Signal & AI Driven Stock Reports - BỘ NỘI VỤ
Is AI-Driven Imaging Innovation Changing the Investment Case for Hologic (HOLX)? - Yahoo Finance
New Clinical Evidence Bolsters Hologic's Breast Cancer Technologies - sharewise.com
Breast Imaging Market Trends, Revenue and Competition Forecast to 2033 Featuring GE Healthcare, Hologic, Philips Healthcare, Gamma Medica, Siemens Healthcare and MoreResearchAndMarkets.com - The AI Journal
Here's Why Hologic (HOLX) is a Strong Value Stock - Yahoo Finance
New Clinical Evidence on Hologic's AI-Powered Mammography Solutions Will Be Unveiled at RSNA - MarketScreener
Hologic (HOLX): Assessing Valuation After RSNA Conference Reveals New Breast Imaging and AI Advances - Sahm
US STD Diagnostics Market Forecast and Company Analysis 2025-2033 Featuring Abbott, F. Hoffmann-La Roche, Hologic, BD and Co, Danaher, Siemens, bioMerieux, Thermo Fisher Scientific, Qiagen, Bio-Rad - GlobeNewswire
New Clinical Evidence on Hologic’s AI-Powered Mammography Solutions Will Be Unveiled at RSNA - Hologic
Longaeva Partners L.P.'s Hologic Inc(HOLX) Holding History - GuruFocus
New Clinical Evidence on Hologic’s AI-Powered Mammography Solutions Will Be Unveiled at RSNA (2025-11-25) - Seeking Alpha
What analysts say about Hologic Inc stockEarnings Call Summaries & Market Crushing Stock Picks - earlytimes.in
Should You Add RattanIndia Power Limited Stock to Your Portfolio Now - earlytimes.in
GE HealthCare to acquire Intelerad for $2.3B - Radiology Business
Halper Sadeh LLC Encourages FRGE, BHF, HOLX Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Hologic's GYN Surgical Delivers a Standout Quarter: What's Behind It? - sharewise.com
Here Are Friday’s Top Wall Street Analysts Research Calls: Advanced Micro Devices, Block, Broadcom, Exact Sciences, Hologic, Palo Alto Networks and More - Yahoo Finance
Will Hologic Inc. (HO1) stock justify high valuation2025 Stock Rankings & Daily Entry Point Trade Alerts - newser.com
BNP Paribas Exane Downgrades Hologic to Neutral From Outperform, Adjusts PT to $79 From $75 - MarketScreener
Can Hologic Inc. (HO1) stock attract ESG investmentsRisk Management & Technical Pattern Alert System - newser.com
Here Are Friday's Top Wall Street Analysts Research Calls: Advanced Micro Devices, Block, Broadcom, Exact Sciences, Hologic, Palo Alto Networks and More - 24/7 Wall St.
Hologic About to Dominate Women’s Health? The Surge Behind Its Global Growth! - Smartkarma
Is a relief rally coming for Hologic Inc. holdersJuly 2025 Outlook & AI Enhanced Trading Signals - newser.com
Why the Narrative Around Hologic Is Changing After the Blackstone and TPG Acquisition News - Yahoo Finance
Why Hologic Inc. stock remains on buy listsJuly 2025 Pullbacks & Long-Term Growth Plans - newser.com
Is Hologic Inc. stock a dividend growth opportunityJuly 2025 Patterns & Fast Entry and Exit Trade Plans - newser.com
Will Hologic Inc. (HO1) stock benefit from Fed rate cutsJuly 2025 Big Picture & Low Risk High Win Rate Stock Picks - newser.com
Is Hologic Inc. (HO1) stock cheap vs fundamentalsAnalyst Upgrade & Weekly Return Optimization Plans - newser.com
Will Hologic Inc. (HO1) stock maintain strong growthProduct Launch & Weekly High Conviction Ideas - newser.com
Hologic Inc Stock (HOLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Hologic Inc Stock (HOLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Stamoulis Christiana | Director |
Oct 20 '25 |
Sale |
73.07 |
7,402 |
540,864 |
47,336 |
1.74%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):